SUMMARY -Chronic heart failure places heavy burden on patients, their families and on health care resources, accounting for high numbers of hospital admissions. Despite huge improvements in the treatment of many heart disorders, the clinical syndrome of chronic heart failure as a fi nal pathway of heart pathology is an exception, in that its prevalence is rising, and only small prolongations in survival are occurring. It is associated with high morbidity and poor prognosis, and a survival rate worse than that for some malignant tumors. Th e reasons for the increasing overall prevalence of chronic heart failure in developed countries lie in prolonged survival owing to modern pharmacological or invasive treatment, better secondary prevention, and aging of the population. Chronic pulmonary disease is common in patients with chronic heart failure. Th rough sharing some risk factors and overlapping pathophysiological processes, they present diagnostic and therapeutic challenge. Th e aim of this article is to review various mechanisms responsible for the symptoms of chronic heart failure with consecutive pulmonary interaction and abnormalities in lung function.
Introduction
Chronic heart failure (CHF) is a clinical syndrome defi ned by the presence of symptoms, most often as breathlessness and fatigue, and objective clinical signs such as evidence of fl uid retention, tachypnea, tachycardia, pleural eff usion, pulmonary rales, or ankle swelling. Of course, to establish the diagnosis, these clinical data have to be combined with objective evidence for structural or functional abnormality of the heart. CHF is always a result of the underlying cardiac disease irrespective of whether it involves the myocardium, endocardium with valvar apparatus, or pericardium. Th e incidence of CHF is reported to be between 2.0% and 5.0 cases per 1000 people per year in western countries, with the increase in the incidence to up to 40 cases per 1000 people per year in the population older than 75 years. Th e prevalence of this condition is estimated to be around 3% with a rise in the prevalence to between 3.0% and 13.0% in the population older than 65 1 . Th e reasons for the increasing overall prevalence of CHF in developed countries lie in prolonged survival owing to modern pharmacological or invasive treatment, better secondary prevention, and aging of the population. Th us, overall expenditures are rising with approximately 2% of national health budgets being spent on the treatment of these patients 2 .
Th e prognosis in CHF is generally poor. A population based study, Framingham Heart Study, showed the median survival of 3.2 years in men and 5.4 years in women after establishing the diagnosis 3 . Also, mortality as a consequence of CHF increases with age, showing a 27% increase in mortality in men with every de-cade of life and 61% increase in women of older age groups 4 . Th e aim of this article is to review the cardiopulmonary interaction of CHF with consecutive pulmonary abnormalities. Th e pathophysiology and treatment of acute heart failure was not considered.
Mechanism and Clinical Impact of Dyspnea in Chronic Heart Failure
Dyspnea or breathlessness is the most common symptom of CHF, largely due to the lower quality of life in these patients. Clinical follow-up, treatment and prognostication in CHF have been traditionally based on the New York Heart Association Functional Classifi cation (NYHA), which is based on clinical criteria, primarily dyspnea and exercise intolerance. Shortness of breath or dyspnea is a product of a well-defi ned, complicated interaction between periphery and cortex of the brain. Namely, various receptors contribute to the process. Hypoxia stimulates peripheral and central chemoreceptors: mechanical stimuli activate mechanoreceptors in upper airways of the chest wall, whereas lung comprises pulmonary stretch receptors, which are activated by lung infl ation; irritant receptors are activated with chemical stimuli, which promote bronchoconstriction and C-fi bers that are placed in the interstitium and react to pulmonary congestion 5 . Breathlessness in CHF is mainly based on the increased breathing eff ort secondary to changes of lung or chest wall mechanics and respiratory musculature weakness, although a signifi cant role is played by pulmonary congestion and changes in lung function. Many patients in stable condition with no volume overload, unlike subjects with chronic pulmonary diseases, are not hypoxemic. Changes in lung and chest wall mechanics take place due to fl uid retention. Left ventricular failure leads to higher end-diastolic ventricular pressure and pulmonary venous hypertension. Th ere is a gradual increase in pulmonary blood fl ow from the apex to the base of the lung, which can be expected. Elevated pressure makes blood fl ow uniformly spread and redistributed across the lung. Th is pulmonary blood fl ow redistribution is accomplished through capillary recruitment. If the rise of the pulmonary venous pressures continues, fl uid would cross the alveolocapillary barrier. Th is process has been traditionally defi ned since Starling fi rst described the basic forces regulating fl uid migration, with hydrostatic forces favoring the crossing of the fl uid to alveolar spaces and interstitial oncotic pressures supporting retention of the fl uid in the interstitial spaces. Over time, the fl uid is being retained in interlobular septa, peribronchovascular interstitium and pleural space with lymphatic system clearing the water overload. Alveolocapillary membrane changes with thickening and fi brosis taking place, which reduces the permeability for fl uid. Also, pulmonary veins become thicker and pulmonary arterioles show intimal fi brosis and media thickening. Th ese changes are responsible for relative resistance of the interstitium to high capillary pressures and have been designated as an explanation of how patients with CHF tolerate high pulmonary capillary wedge pressures without experiencing pulmonary edema. Fluid overload in the interstitium, peribronchovascular, hilar and pleural spaces is responsible for lower pulmonary compliance and higher chest stiff ness. Because of the long-lasting process of pulmonary venous hypertension in CHF, sometimes damage to alveolocapillary area occurs 6 . Namely, tearing of alveolar epithelium, capillary endothelium and collagen structures of basal membranes takes place and is responsible for extravasation of red blood cells into the alveolar spaces (Fig.  1) . Th is process has been termed pulmonary capillary stress failure. Also, this explains the higher content of hemosiderin in alveolar spaces in patients with long- Fig. 1 standing chronic heart failure, sometimes leading even to pulmonary ossifi cation. Such changes have been especially well described in patients with long-standing mitral stenosis 7 .
Th e Role of Respiratory Musculature in Dyspnea and Exercise Intolerance in Patients with Chronic Heart Failure
Respiratory eff ort can be simply defi ned by the sense of 'breathing work' needed to fulfi ll ventilatory demand in a hypothetical situation. Th is awareness of eff ort is a function of the ratio between generated work achieved by respiratory muscles in that hypothetical situation and their maximum capability. Th us, the sense of eff ort is increased whenever muscles have to generate greater pressure in order to compensate for extra load (such as higher elastic or resistive forces of the lung or chest), or when there is lower pressure generating the capacity of muscles (intrinsic weakness of the respiratory musculature, increase in the chest volume, fatigue of the musculature). A large number of experimental and clinical works have been dedicated to enlighten the role of respiratory musculature in CHF. Most of the work of breathing is done by the diaphragm consisting of 'slow oxidative-fatigue resistant' fi bers, which are, on the other hand, very perfusion sensitive. It has been shown that patients with CHF have a signifi cantly reduced strength of respiratory musculature as compared with healthy individuals of the same age 8 . Moreover, in these patients, muscle strength of other regions in the body has not been reduced in that scale, leading to a conclusion that respiratory muscles depend more on the cardiac output but there are reports suggesting that this disorder is a general one, with respiratory muscles to be aff ected earlier 9 . McParland et al. proved that respiratory muscle strength was reduced in patients with CHF, and what is more, that this reduction of respiratory muscle strength correlated with dyspnea on performing everyday activities 10 . In another study, McParland et al. confi rmed these fi ndings and found no connection of muscle weakness with nutritional or electrolyte status in patients with CHF
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. Mancini et al. demonstrated hypoxia to take place in respiratory muscles during exercise in patients with CHF; in a subsequent study, Mancini et al. showed not only linear connection between respiratory muscle strength and dyspnea, but also changes of diaphragm workload and lack of muscle fatigue during exercise in patients with cardiac failure 12, 13 . In another study by Evans et al., weakness of respiratory muscles in CHF was found again, but without correlation with dyspnea or exercise intolerance 14 . Respiratory muscle endurance defi ned as the ability of the muscle to resist fatigue is a sign of respiratory musculature dysfunction, which is depressed in CHF patients and tends to correlate with their exercise intolerance 15, 16 . Relative inconclusiveness of various studies regarding the connection between respiratory muscle dysfunction and dyspnea or exercise intolerance may be a consequence of diff erent methodology, small number of patients, or variability of patient characteristics. Nevertheless, rehabilitation and training of inspiratory muscles in patients with CHF showed clear benefi t [17] [18] [19] .
Lung Function in Chronic Heart Failure
Changes in lung functions in patients with CHF have been well studied. As regards the fact that dyspnea is the most frequent of all symptoms in these patients, great interest was directed towards understanding of the underlying process. Respective studies used pulmonary function testing and showed that patients with CHF predominantly had a restrictive pattern of breathing. Th ere are several reasons that can explain such fi ndings. Firstly, these patients exhibit volume overload with liquid retention in pulmonary interstitial, alveolar and pleural spaces. Secondly, the size of the heart is enlarged. Agostoni et al. conducted a study in which cardiothoracic index on conventional chest x-ray correlated inversely with the parameters of lung function 20 . Th irdly, stiff ness of the lung due to water retention contributes as well. Bearing the fact of unique thoracic space in mind, which comprises heart, lungs and other structures in a given volume, these changes are directly reducing the useful lung volume. Indeed, the relation between cardiomegaly and deterioration of lung function was directly studied showing positive correlation 20 . Lung function testing in CHF predominantly shows reduced total lung capacity (TLC) and forced vital capacity (FVC) [21] [22] [23] . Consequently, the ratio between forced expiratory volume in fi rst second (FEV1) and FVC is increased. Also, residual volume tends to be increased with reduction of vital capacity. Namely, accumulation of retained liquid in peribronchovascular spaces leads to erection of distended vessels and compression of bronchioles with air trapping 24 . After intensive diuretic treatment or heart transplantation, all of these changes tend to be corrected [25] [26] [27] . Acute heart failure shows completely diff erent lung function disturbance patterns with predominantly obstructive changes in lung function testing 28, 29 . Th is explains wheezing in clinical presentation of such patients. Th e reason for this lies in airway obstruction due to wall congestion of smaller airways. All of these changes have also been shown to improve following diuretic therapy, although it is interesting that bronchodilator therapy did not improve airway obstruction 28 . Finally, bronchial hyperreactivity in CHF may play a signifi cant role. Th is can be explained by congestion and thickening of the bronchial mucosa layer with activation of irritant receptors and C-fi bers. Vagotomy in experimental animals put in the setting of cardiac failure has shown betterment of lung function 30 . Indeed, patients with CHF were shown to have significantly higher bronchial hyperreactivity with acetylcholine inhalation testing 31 . Lung function during physical activity in patients with CHF shows striking change with regard to the pathologic pattern of ventilation in which patients produce higher respiratory rate with low tidal volume, in contrast to healthy subjects where physical demand is met with the increase in both tidal volume and respiratory frequency, yielding a higher ventilation rate in patients with congestive CHF for a given workload. Th ere are several explanations, most important being changes in lung mechanics with the increase in the overall chest volume and stiff ness, lower lung compliance, all of which make respiratory muscles ineff ective, weak and prone to fatigue. Moreover, lung diff usion is reduced and dead space ventilation is increased 23 . Th is hyperventilating pattern correlates with the rate of dyspnea and physical exercise intolerance 32, 33 . Also, the severity and prognosis of CHF can be estimated with low ventilatory effi ciency defi ned as high ventilation drive relative to the given carbondioxide production [34] [35] [36] .
Lung Diff usion in Chronic Heart Failure
Gas diff usion takes place at the alveolocapillary membrane which, in a simplifi ed model, consists of alveolar epithelium, capillary endothelium, and their basal membranes. Electron microscopy has shown that this membrane is not uniformly structured but is composed of a thinner and thicker part with regard to the interstitial matrix content. On the thinner side, capillary endothelium and alveolar epithelium are closely positioned with tight junctions and basal membranes fused, whereas on the thicker side these structures are mediated by the protein-rich interstitium 37 . Th in part of the membrane is designed to optimally fulfi ll the task of gas diff usion, and the thick part, in the setting of higher hydrostatic pressures (as in CHF), takes over the fl uid and removes it from the critical area where gas diff usion takes place. Generally, diff using capacity of the lung for carbon monoxide (DLCO) is a function of membrane conductance on the one hand, and of the blood volume in the capillaries with the rate of hemoglobin on the other hand. Patients with CHF were shown to have reduced DLCO with linear deterioration of lung diff usion in patients with more severe CHF [38] [39] [40] . Th e reason for reduced DLCO presumably lies in chronic changes of the alveolocapillary membrane with fl uid accumulation, fi brosis, and subsequent reduction of membrane conductance. Also, this reduction is obviously not compensated enough with larger volume of capillary blood fl ow as would be expected giving the fact of pulmonary venous hypertension in these patients. Also, these changes are not completely reversible because patients after heart transplantation keep approximately the same DLCO as before the operation 41, 42 . After heart transplantation, DLCO tends to decline at fi rst, which probably resembles the decline in capillary blood fl ow due to reduction in pulmonary venous pressure [43] [44] [45] . All these changes show that DLCO reduction in patients with CHF does not depend solely on fl uid retention but rather is a longlasting process with formation of chronic changes to alveolocapillary membrane, or may be a consequence of accompanying pulmonary disease. Th is conclusion is supported by the fact that ultrafi ltration in patients with CHF improves lung volumes and mechanical properties of the lung but is unable to improve DLCO, which means that this parameter is not completely fl uid-dependent 46 . Impaired lung diff usion was shown to be related to depressed exercise capacity in patients with heart failure [47] [48] [49] . Also, membrane conductance, of all respiratory function parameters, correlated best with exercise ventilation effi ciency and prognosis in patients with heart failure 50, 51 . Exercise training in pa-tients with heart failure can improve DLCO and exercise performance 52 .
Ventilation-Perfusion Mismatch in Chronic Heart Failure
As mentioned above, redistribution of pulmonary capillary perfusion takes place in patients with cardiac failure due to pulmonary venous hypertension and volume overload. Changes of lung volumes and mechanics also occur. Th is makes patients with CHF more prone to ventilation-perfusion mismatching. In normal conditions, there is no alveolar dead space but, rather, dead space is a consequence of anatomic dead space. It has been shown that exercise ventilation pattern in CHF is a pathologic one with hyperventilation and low effi ciency. Th e reason, among others mentioned earlier, lies in the inability of the lung to augment tidal volume during exercise, which makes breathing in these conditions shallow and rapid. Also, the ratio between the dead space volume and tidal volume stays constant in exercise, suggesting that there are areas of high ventilation-perfusion mismatch with under perfused alveolar spaces, probably due to low cardiac output 53 . Th ese facts when summarized bring us to a conclusion that there is a connection between low effi cient breathing, exercise intolerance and ventilation-perfusion mismatch with high respiratory drive to compensate for the under perfused areas of the lung 54 .
Sleep Disordered Breathing in Chronic Heart Failure
Chronic heart failure is tightly connected with sleep-disordered breathing (SDB). SDB can be divided into obstructive sleep apnea/hypopnea (OSA), which is defi ned as fi ve or more apnea/hypopnea episodes per hour (apnea/hypopnea index, AHI) that occur due to obstruction of upper airways, combined with extreme respiratory eff ort and central sleep apnea (CSA), which is defi ned the same as OSA but without traceable respiratory eff ort during apnea/hypopnea episodes [55] [56] [57] [58] [59] [60] . Both OSA and CSA can coexist in some patients. CSA can be accompanied with CheyneStokes respiration, periodic breathing where apneas alternate with rapidly emerging and waning ventilation. Among patients with CHF, 50% of them suff er from SDB, with 80% of them having CSA and the rest having OSA 61 . OSA/CSA result in repetitive oxyhemoglobin desaturations with consequential arousals, activation of sympathetic system, and increase in arterial blood pressure. OSA is thought to be a major causal factor for cardiovascular diseases and CHF, fi rstly through its clear eff ect on the incidence of arterial hypertension as a major cardiovascular risk factor, then through mechanical and hemodynamic eff ects of negative intrathoracic pressures; OSA has also been associated with activation of the sympathetic nervous system, endothelial dysfunction and systemic infl ammation [62] [63] [64] [65] [66] [67] . CSA with or without Cheyne-Stokes respiration pattern is a consequence of CHF. Th is form of SDB occurs due to instability of the respiratory system in patients with CHF [68] [69] . Respiration during sleep is controlled by the interaction between brainstem centers, respiratory apparatus (inspiratory musculature, pulmonary parenchyma) and chemoreceptors. Tight correlation between the ventilatory cycle duration and left ventricular ejection fraction has led to a conclusion that low cardiac output and timely transport of the chemostimuli to the chemoreceptors are responsible for the prolonged ventilatory cycle in CHF patients 70 . Th us, chemoreceptors produce an exaggerated answer to low partial pressures of carbon dioxide, fi nally leading to apnea or hypopnea. Low partial pressure of carbon dioxide is, on the other hand, a consequence of hyperventilation or high respiratory drive in CHF. It is believed that partial pressure of carbon dioxide is the most important indicator of respiratory drive control, as confi rmed by a study with reversal of CSA with carbon dioxide inhalation 71 . CSA can worsen the existing CHF through its eff ect on further activation of the sympathetic system, hypoxemia, blood pressure variations, and cardiac arrhythmia, and also worsens the prognosis with increase of mortality in patients with higher AHI 72 . Sleep breathing disorders in CHF can be improved with treatment. OSA has been successfully treated with continuous positive airway pressure 68 . Studies with optimization of chronic pharmacotherapy have shown success in treating CSA in patients with CHF; supplementing oxygen via nasal cannula has also been shown eff ective 74, 75 . Th e administration of bronchodilation agents showed benefi cial eff ect on SDB and acetazolamide-mild diuretic given before sleep produces mild metabolic acidosis, therefore decreases partial pressure of carbon dioxide and resets the apnea/hypopnea threshold resulting in fewer episodes of apnea, better oxyhemoglobin saturation, and improving the quality of sleep 76, 77 . Noninvasive continuous positive airway pressure treatment reduces sympathetic system activation, arrhythmia incidence, arterial hypertension, and improves left ventricular ejection fraction and volume 78, 79 . Th ere is no clear effect on mortality reduction 80 .
Radiographic Manifestation of Chronic Heart Failure
Chronic heart failure with pulmonary venous hypertension and volume overload brings along characteristic radio-morphological changes in thoracic imaging. Conventional chest radiogram has been traditionally considered to be the most appropriate tool for diagnosis and follow-up of CHF. Normally, pulmonary blood fl ow has its characteristic distribution pattern with better perfused area of the lung being its basal part and less perfused area of the lung being the apex, accordingly with gravitational force. Pulmonary blood fl ow is a low-pressure and low-resistance system with large capacity for accommodation in case of pulmonary venous hypertension and volume overload. Rise in left ventricular end-diastolic pressure, which can be approximated with the rise in pulmonary capillary wedge pressure, in patients with CHF leads to changes in pulmonary blood fl ow. Capillaries in the apical parts of the lung, previously collapsed, are being recruited and those in the base of the lung are being distended. Th is change in physiological perfusion of the lung is called redistribution of the pulmonary blood fl ow. Logically, pulmonary artery-to-bronchus diameter ratio changes as well. Namely, with volume overload arteries gain greater diameter and surpass diameter of the accompanying bronchus, especially in lower parts of the lung 81 . Cardiomegaly is another typical radiographic sign of congestive CHF, although not especially sensitive or specifi c. It has sensitivity of 50% and specifi city of around 75%. Cardiomegaly is best appreciated through cardiothoracic ratio. Th is ratio is calculated by dividing transverse cardiac diameter with transverse chest diameter measured on chest x-ray, and cardiomegaly is present when the ratio surpasses 50%. Another feature of the heart silhouette on chest x-ray, vascular pedicle, which comprises great intrathoracic vessels, widens on chest x-ray. Th is pedicle is routinely measured as a fi eld that is limited on the right with superior vena cava and on the left with the point of the subclavian artery take-off . Normally, this diameter is 6.0 centimeters or less and is considered pathological when 8.5 centimeters or greater. Th e azygos vein seen on the chest x-ray when dilated is a sign of increased right atrial pressure. Normal diameter of the vein is about 7.0 millimeters and when the diameter is 10.0 or more millimeters, it should be considered abnormal and suggests volume overload. As pulmonary venous pressure keeps rising, interstitial edema is formed 82, 83 . It is a consequence of fl uid leakage into the interlobular and peribronchial interstitium. When the fl uid leaks into peripheral interlobular interstitium, it can be appreciated as Kerley B lines on chest x-ray. Th ese are peripherally mounted small horizontal lines that run perpendicularly to the pleura. Edema of the peribronchial interstitium presents as bronchial wall thickening. If pulmonary venous pressure would increase further, alveolar edema and fl ooding of alveolar spaces would take place. Computerized tomography of the chest is not a method of choice for screening or follow-up of patients with CHF for being expensive, relatively inaccessible, and associated with high radiation dose, although patients with CHF demonstrate typical fi ndings such as interstitial edema with thickened septal lines and ground glass opacities in dependent part of the lung [82] [83] [84] (Fig. 2) . 
Conclusion
Evaluation of cardiac and pulmonary function and interactions between CHF and consequential chronic lung disease is complex and incompletely understood, often problematic and occasionally misleading. Both conditions are systemic disorders with overlapping pathophysiological processes, and they present diagnostic and therapeutic challenge. Pulmonary function is frequently abnormal, with a decrease in vital capacity shown to precede clinical recognition of CHF. DLCO is often mildly reduced and does not normalize following heart transplantation. Reduced lung compliance, increased dead space ventilation, and muscle weakness contribute to the preceding abnormalities in producing exercise limitation. Sleep apnea, particularly of the central variety, is associated with chronic CHF and confers worse prognosis. Various limitations of clinical evaluation may lead to diffi culties in the diagnosis, and consequently in the treatment of CHF, particularly when the presentation is atypical or when lung disease already exists. Th e resulting symptomatic and prognostic benefi ts outweigh those attainable by treating either condition alone. Additional studies providing new data on the pathogenesis and management of patients with CHF are needed, with the purpose of trying to improve the quality of life, appropriate treatment, as well as survival of these patients. While many of these therapies will improve the care of patients with CHF, signifi cant reductions in the prevalence will require vigorous, multifaceted, preventive approaches. Only through high appreciation of the complex interactions between the heart and the lung, diagnostic and treatment-related errors can be minimized. A high degree of cooperation is ultimately required among cardiologists, pulmonologists and radiologists in order to better identify and manage these clinical entities. All clinicians attending these patients should perform an integrated approach to objectively identify both diseases at an early stage, and to optimize control of respiratory and cardiovascular conditions.
